C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 76 filers reported holding C4 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $777,930 | -59.8% | 418,242 | -40.5% | 0.00% | – |
| Q2 2023 | $1,933,476 | +10.1% | 703,082 | +25.8% | 0.00% | – |
| Q1 2023 | $1,755,430 | -24.2% | 559,054 | +42.4% | 0.00% | -100.0% |
| Q4 2022 | $2,316,341 | +81.7% | 392,600 | +170.0% | 0.00% | – |
| Q3 2022 | $1,275,000 | +332.2% | 145,387 | +271.3% | 0.00% | – |
| Q2 2022 | $295,000 | -91.5% | 39,151 | -72.6% | 0.00% | -100.0% |
| Q1 2022 | $3,467,000 | -40.3% | 142,929 | -20.8% | 0.00% | 0.0% |
| Q4 2021 | $5,811,000 | +174.2% | 180,456 | +280.4% | 0.00% | – |
| Q3 2021 | $2,119,000 | -57.7% | 47,435 | -64.2% | 0.00% | -100.0% |
| Q2 2021 | $5,013,000 | +569.3% | 132,478 | +554.2% | 0.00% | – |
| Q1 2021 | $749,000 | -78.2% | 20,251 | -80.5% | 0.00% | -100.0% |
| Q4 2020 | $3,441,000 | – | 103,873 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |